Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Common Equity (2016 - 2025)

Historic Common Equity for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to $654.3 million.

  • Ocular Therapeutix's Common Equity rose 10749.09% to $654.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $654.3 million, marking a year-over-year increase of 10749.09%. This contributed to the annual value of $654.3 million for FY2025, which is 10749.09% up from last year.
  • As of Q4 2025, Ocular Therapeutix's Common Equity stood at $654.3 million, which was up 10749.09% from $258.2 million recorded in Q3 2025.
  • Over the past 5 years, Ocular Therapeutix's Common Equity peaked at $654.3 million during Q4 2025, and registered a low of $3.1 million during Q2 2023.
  • For the 5-year period, Ocular Therapeutix's Common Equity averaged around $180.8 million, with its median value being $87.7 million (2021).
  • Its Common Equity has fluctuated over the past 5 years, first crashed by 9530.87% in 2023, then surged by 1213501.78% in 2024.
  • Over the past 5 years, Ocular Therapeutix's Common Equity (Quarter) stood at $88.0 million in 2021, then tumbled by 59.8% to $35.4 million in 2022, then surged by 157.59% to $91.1 million in 2023, then surged by 246.03% to $315.3 million in 2024, then skyrocketed by 107.49% to $654.3 million in 2025.
  • Its Common Equity was $654.3 million in Q4 2025, compared to $258.2 million in Q3 2025 and $305.9 million in Q2 2025.